Evaluation of dose differences between intracavitary applicators for cervical brachytherapy using knowledge-based models

被引:3
|
作者
Kallis, Karoline [1 ]
Mayadev, Jyoti [1 ]
Covele, Brent [1 ]
Brown, Derek [1 ]
Scanderbeg, Daniel [1 ]
Simon, Aaron [1 ]
Frisbie-Firsching, Helena [1 ]
Yashar, Catheryn M. [1 ]
Einck, John P. [1 ]
Mell, Loren K. [1 ]
Moore, Kevin L. [1 ]
Meyers, Sandra M. [1 ]
机构
[1] Univ Calif San Diego, Dept Radiat Med & Appl Sci, San Diego, CA 92103 USA
基金
美国国家卫生研究院; 美国医疗保健研究与质量局;
关键词
Knowledge-based planning; Dose prediction; Cervical cancer; Intracavitary brachytherapy; Tandem and ovoids; Tandem and ring; HDR-BRACHYTHERAPY; CANCER BRACHYTHERAPY; RADIATION-THERAPY; WORKING GROUP; OPTIMIZATION; TANDEM; ALGORITHM; ANATOMY; QUALITY; RING;
D O I
10.1016/j.brachy.2021.08.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: Currently, there is a lack of patient-specific tools to guide brachytherapy planning and applicator choice for cervical cancer. The purpose of this study is to evaluate the accuracy of organ-at-risk (OAR) dose predictions using knowledge-based intracavitary models, and the use of these models and clinical data to determine the dosimetric differences of tandem-and-ring (T&R) and tandem-and-ovoids (T&O) applicators. MATERIALS AND METHODS: Knowledge-based models, which predict organ D-2cc, were trained on 77/75 cases and validated on 32/38 for T&R/T&O applicators. Model performance was quantified using Delta D-2cc=D-2cc,D-actual-D-2cc,D-predicted, with standard deviation (sigma(AD(2cc))) representing precision. Model-predicted applicator dose differences were determined by applying T&O models to T&R cases, and vice versa, and compared to clinically-achieved D2cc differences. Applicator differences were assessed using a Student's t-test (p < 0.05 significant). RESULTS: Validation T&O/T&R model precision was 0.65/0.55 Gy, 0.55/0.38 Gy, and 0.43/0.60 Gy for bladder, rectum and sigmoid, respectively, and similar to training. When applying T&O/T&R models to T&R/T&O cases, bladder, rectum and sigmoid D-2cc values in EQD2 were on average 5.69/2.62 Gy, 7.31/6.15 Gy and 3.65/0.69 Gy lower for T&R, with similar HRCTV volume and coverage. Clinical data also showed lower T&R OAR doses, with mean EQD2 D-2cc deviations of 0.61 Gy, 7.96 Gy (p < 0.01) and 5.86 Gy ( p < 0.01) for bladder, rectum and sigmoid. CONCLUSIONS: Accurate knowledge-based dose prediction models were developed for two common intracavitary applicators. These models could be beneficial for standardizing and improving the quality of brachytherapy plans. Both models and clinical data suggest that significant OAR sparing can be achieved with T&R over T&O applicators, particularly for the rectum. (C) 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1323 / 1333
页数:11
相关论文
共 50 条
  • [21] Improving plan quality in cervical cancer brachytherapy using knowledge-based planning for direction modulated brachytherapy tandem applicator
    Gautam, Suman
    Flower, Emily
    Richeson, Dylan
    Sangha, Ikchit
    Ma, Tianjun
    Song, William Y.
    BRACHYTHERAPY, 2025, 24 (01) : 144 - 153
  • [22] Dose comparison between prescription methods according to anatomical variations in intracavitary brachytherapy for cervical cancer
    Choi, Euncheol
    Kim, Jae Ho
    Kim, Ok Bae
    Byun, Sang Jun
    Kim, Jin Hee
    Oh, Young Kee
    RADIATION ONCOLOGY JOURNAL, 2018, 36 (03): : 227 - 234
  • [23] An Assessment of Organ-at-Risk Dose and Interfraction Variability Using 4 Different Applicators for Intracavitary Gynecologic HDR Brachytherapy
    Banerjee, R. N.
    Park, S. J.
    Wang, J.
    Kayode, O.
    Demanes, D. J.
    Kamrava, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S421 - S421
  • [24] Concurrent chemoradiotherapy using high-dose rate intracavitary brachytherapy for uterine cervical cancer
    Song, E.
    Lee, N.
    Kwak, J.
    Kim, J.
    Lee, H. K.
    Yim, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer
    Toita, T
    Moromizato, H
    Ogawa, K
    Kakinohana, Y
    Maehama, T
    Kanazawa, K
    Murayama, S
    GYNECOLOGIC ONCOLOGY, 2005, 96 (03) : 665 - 670
  • [26] Dose Calculation in Gynecological Brachytherapy using Monte Carlo simulation for intracavitary treatment of Cervical Cancer
    Garcia Contreras, O. J.
    Cristancho, F.
    WORLD CONGRESS ON MEDICAL PHYSICS AND BIOMEDICAL ENGINEERING, 2015, VOLS 1 AND 2, 2015, 51 : 452 - 455
  • [27] Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer
    Toita, T
    Moromizato, H
    Kakinohana, Y
    Maehama, T
    Nagai, Y
    Ogawa, K
    Tamaki, W
    Kanazawa, K
    Murayama, S
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S292 - S292
  • [28] Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer
    Kirisits, C
    Pötter, R
    Lang, S
    Dimopoulos, J
    Wachter-Gerstner, N
    Georg, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (03): : 901 - 911
  • [29] Dose volume histogram analysis of MRI-based intracavitary pulsed dose rate brachytherapy in cervical cancer
    Lindegaard, J.
    Tanderup, K.
    Gelineck, J.
    Nielsen, S. K.
    Christensen, J. J.
    Christensen, T. B.
    Nyvang, G-B.
    Jurik, A. G.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S78 - S78
  • [30] Megavoltage CT image-based intracavitary low dose rate brachytherapy for cervical carcinoma
    Wagner, TH
    Buchholz, D
    Forbes, A
    Willoughby, TR
    Meeks, SL
    Kupelian, PA
    Zeidan, OA
    Langen, KM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S338 - S339